Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DICERNA PHARMACEUTICALS, INC.

(DRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization1 6711 5081 6531 674--
Entreprise Value (EV)1 3681 5081 6531 1741 3131 471
P/E ratio -6,68x-12,5x-14,5x-11,5x-18,0x-9,01x
Yield ------
Capitalization / Revenue 109x63,1x10,1x9,37x8,42x11,8x
EV / Revenue 59,6x63,1x10,1x6,57x6,60x10,3x
EV / EBITDA ----9,52x-7,33x-6,92x
Price to Book ------
Nbr of stocks (in thousands) 62 73268 43175 04577 734--
Reference price (USD) 10,722,022,021,521,521,5
Announcement Date 03/11/201902/27/202002/25/2021---
1 USD in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales1 6,1823,9164179199142
EBITDA1 ----123-179-212
Operating profit (EBIT)1 -90,4-128-113-144-123-219
Operating Margin -1 463%-536%-68,9%-80,7%-61,6%-154%
Pre-Tax Profit (EBT)1 -88,9-120-113-143-97,4-209
Net income1 -88,9-120-113-144-97,4-209
Net margin -1 439%-504%-68,6%-80,4%-49,0%-147%
EPS2 -1,60-1,76-1,52-1,88-1,20-2,39
Dividend per Share2 ------
Announcement Date 03/11/201902/27/202002/25/2021---
1 USD in Million
2 USD
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2020 Q4 2021 Q1 2021 Q2 2021 Q3 2021 Q4 2022 Q1
Net sales1 41,047,641,343,850,731,6
EBITDA ------
Operating profit (EBIT)1 -31,6-29,1-40,2-36,8-33,5-50,7
Operating Margin -77,3%-61,1%-97,4%-83,9%-66,2%-160%
Pre-Tax Profit (EBT)1 -36,6-30,0-40,3-38,4-33,7-46,1
Net income1 -36,6-30,0-40,8-38,4-33,7-46,1
Net margin -89,3%-62,9%-98,7%-87,8%-66,6%-146%
EPS2 -0,49-0,39-0,53-0,50-0,44-0,58
Dividend per Share ------
Announcement Date 02/25/202105/06/202108/09/2021---
1 USD in Million
2 USD
Previous periodNext period
Balance Sheet Analysis
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt1 ------
Net Cash position1 303--501362204
Leverage (Debt / EBITDA) ---4,06x2,02x0,96x
Free Cash Flow1 17,9-7,04163-85,77,20-1,40
ROE (Net Profit / Equities) ----163%-232%-801%
Shareholders' equity1 ---88,241,926,1
ROA (Net Profit / Asset) ------
Assets1 ------
Book Value Per Share ------
Cash Flow per Share ------
Capex1 0,366,3511,719,326,714,1
Capex / Sales 5,81%26,6%7,15%10,8%13,4%9,90%
Announcement Date 03/11/201902/27/202002/25/2021---
1 USD in Million
Key data
Capitalization (USD) 1 674 394 064
Net sales (USD) 164 307 000
Number of employees 302
Sales / Employee (USD) 544 063
Free-Float 91,8%
Free-Float capitalization (USD) 1 536 696 491
Avg. Exchange 20 sessions (USD) 11 732 051
Average Daily Capital Traded 0,70%
EPS & Dividend